CVS Health Corp’s recently made public that its Director Mahoney Michael F acquired Company’s shares for reported $0.5 million on May 02 ’24. In the deal valued at $54.49 per share,9,181 shares were bought. As a result of this transaction, Mahoney Michael F now holds 9,356 shares worth roughly $0.52 million.
Then, LUDWIG EDWARD J bought 1,000 shares, generating $53,879 in total proceeds. Upon buying the shares at $53.88, the Director now owns 21,630 shares.
Before that, Shah Prem S sold 29,473 shares. CVS Health Corp shares valued at $2,267,947 were divested by the EVP and Pres-Pharm, Consumer W at a price of $76.95 per share. As a result of the transaction, Shah Prem S now holds 39,765 shares, worth roughly $2.23 million.
UBS downgraded its CVS Health Corp [CVS] rating to a Neutral from a a Buy in a research note published on May 02, 2024; the price target was decreased to $60 from $85. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who decreased its forecast for the stock in early May from “an Outperform” to “a Market perform”. Cantor Fitzgerald also remained covering CVS and has decreased its forecast on May 01, 2024 with a “Neutral” recommendation from previously “an Overweight” rating. Barclays started covering the stock on March 06, 2024. It rated CVS as “an Equal weight”.
Price Performance Review of CVS
On Monday, CVS Health Corp [NYSE:CVS] saw its stock jump 0.13% to $55.97. Over the last five days, the stock has lost -17.02%. CVS Health Corp shares have fallen nearly -29.12% since the year began. Nevertheless, the stocks have fallen -18.64% over the past one year. While a 52-week high of $83.25 was reached on 01/08/24, a 52-week low of $53.70 was recorded on 05/02/24. SMA at 50 days reached $72.29, while 200 days put it at $72.31. A total of 16.59 million shares were traded, compared to the trading of 23.95 million shares in the previous session.
Levels Of Support And Resistance For CVS Stock
The 24-hour chart illustrates a support level at 55.44, which if violated will result in even more drops to 54.90. On the upside, there is a resistance level at 56.39. A further resistance level may holdings at 56.80. The Relative Strength Index (RSI) on the 14-day chart is 15.93, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -9.09, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 86.25%. Stochastics %K at 11.36% indicates the stock is a buying.
The most recent change occurred on February 26, 2024 when Leerink Partners began covering the stock and recommended ‘”an Outperform”‘ rating along with a $88 price target.
